
0.193 Delayed Data As of May 20 | ![]() Today’s Change | 0.19 Today|||52-Week Range 2.32 | -67.77% Year-to-Date |
The 1 analysts offering 12-month price forecasts for Nabriva Therapeutics PLC have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The median estimate represents a +936.27% increase from the last price of 0.19.
The current consensus among 2 polled investment analysts is to Buy stock in Nabriva Therapeutics PLC. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.